Multiple Endocrine Neoplasia Type 2 and the Practice of Molecular Medicine

Reviews in Endocrine and Metabolic Disorders

Volumn 1, Issue 4, 2000, Pages 283-290

  Eng, Charis ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Genotype phenotype; Predictive testing; Prophylactic surgery; RET; Surveillance

Indexed keywords

ANIMAL; GENOTYPE; HUMAN; NEUROFIBROMATOSIS; PATHOPHYSIOLOGY; REVIEW; SIPPLE SYNDROME; THYROIDECTOMY;

ANIMALS; GENOTYPE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; THYROIDECTOMY;

EID: 0034331355     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026514301172     Document Type: Article

References (64)

1. Eng C, Ponder BAJ. Multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. In: Grossman A, ed. Clinical Endocrinology. Oxford: Blackwell Science; 1998;635-650.
2. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17:380-393.
3. Schimke RN, Hartmann WH, Prout TW, Rimoin DL. Syndrome of bilateral pheochromoctyoma, medullary thyroid carcinoma and multiple neuromas. N Engl J Med 1968;279:1-7.
4. Schimke RN. Genetic aspects of multiple endocrine neoplasia. Annu Rev Med 1984;35:25-31.
5. Schuffenecker I, Ginet N, Goldgar D, Eng C, Chambe B, Boneu A, Houdent C, Pallo D, Schlumberger M, Thivolet C, Lenoir GM. Prevalence and parental origin of de novo RET mutations in MEN 2A and FMTC. Am J Hum Genet 1997;60:233-237.
6. Gorlin RJ, Sedano HO, Vickers RA, Cervenka J. Multiple mucosal neuromas, phaeochromocytoma and medullary carcinoma of the thyroid - a syndrome. Cancer 1968;22:293-299.
7. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986;73:278-281.
8. Easton DF, Ponder MA, Cummings T, Gagel R, Hansen HH, Reichlin S, Tashjian AH, Telenius-Berg M, Ponder BAJ. Group CMT. The clinical and age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet 1989;44:208-215.
9. Shannon KE, Gimm O, Hinze R, Dralle H, Eng C. Germline V804M in the RET proto-oncogene in two apparently sporadic cases of MTC presenting in the seventh decade of life. J Endo Genet 1999;1:39-46.
10. Telander RL, Moir CR. Medullary thyroid carcinoma in children. Sem Pediatr Surg 1994;3:188-193.
11. Myers SM, Eng C, Ponder BAJ, Mulligan LM. Characterization of RET proto-oncogene 37prime; splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 1995;11:2039-2045.
12. Gardner E, Papi L, Easton DF, Cummings T, Jackson CE, Kaplan M, Love DR, Mole SE, Moore JK, Mulligan LM, Norum RA, Ponder MA, Reichlin S, Stall G, Telenius H, Telenius-Berg M, Ponder BAJ. Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2. Hum Mol Genet 1993;2:241-246.
13. Santoro M, Rosato R, Grieco M, Berlingieri MT, Luca-Colucci D'Amato G, de Franciscis V, Fusco A. The Ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 1990;5:1595-1598.
14. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T. Expression of the Ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994;172:255-260.
15. Trupp M, Raynoschek C, Belluardo N, Ibanez CF. Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase. Moll Cell Neurobiol 1998;11:47-63.
16. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM, Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha-3-RET receptor complex. Neuron 1998;21:1291-1302.
17. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis J-C, Hu S, Altrock BW, Fox GM. GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-a, a novel receptor for GDNF. Cell 1996;85:1113-1124.
18. Moore MW, Klein RD, Farinas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver-Moore K, Rosenthal A. Renal and neuronal abnormalities in mice lacking GDNF. Nature 1996;382:76-79.
19. Pichel JG, Shen L, Sheng HZ, Granholm A-C, Drago J, Grinberg A, Lee EJ, Huang SP, Saarmas M, Hoffer BJ, Sariola H, Westphal H. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996;382:73-76.
20. Sanicola M, Hession C, Worley D, Carmillo P, Ehrenfels C, Walus L, Robinson S, Jaworski G, Wei H, Tizard R, Whitty A, Pepinsky RB, Cate RL. GDNF-dependent RET activation can be mediated by two different cell-surface accessory proteins. Proc Natl Acad Sci (USA) 1997;94:6238-6243.
21. Sáchez MP, Silos-Santiago I, Frisé J, He B, Lira SA, Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996;382:70-73.
22. Treanor JJS, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A. Characterization of a multicomponent receptor for GDNF. Nature 1996;382:80-83.
23. Trupp M, Arenas E, Fainzilber M, Nilsson A-S, Sleber B-A, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, Arumae U, Sariola H, Saarma M, Ibáez CF. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996;381:785-789.
24. Baloh RH, Tansey MG, Golden JP, Creedon DJ, Heukeroth RO, Keck CL, Zimonjic DB, Popescu NC, Johnson EM, Milbrandt J. TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron 1997;18:793-802.
25. Jing SQ, Yu YB, Fang M, Hu Z, Holst PL, Boone T, Delaney J, Schultz H, Zhou RP, Fox GM. GFR-alpha-2 and GFR-alpha-3 are two new receptors for ligands of the GDNF family. J Biol Chem 1998;272:33111-33117.
26. Thompson J, Doxakis E, Pinon LGP, Strachan P, Buj-Bello A, Wyatt S, Buchman VL, Davies AM. GFRa-4, a new GDNF family receptor. Mol Cell Neurosci 1998;11:117-126.
27. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460.
28. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
29. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-241.
30. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JWM, Ploos van Amstel HK, Romeo G, Lips CJM, Buys CHCM. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994;367:375-376.
31. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA, Goodfellow PJ, Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci (USA) 1994;91:1579-1583.
32. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, Ploos van Amstel HK, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: International RET Mutation Consortium analysis. JAMA 1996;276:1575-1579.
33. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BAJ. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509-513.
34. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, Tourniaire J, Lenoir GM, Romeo G. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995;10:2415-2419.
35. Fink M, Weinhäusel A, Niederle B, Haas OA. Distinction between sporadic and herditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. Int J Cancer 1996;69:312-316.
36. Nilsson O, Tissell L-E, Jansson S, Ahlman H, Gimm O, Eng C. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 1999;281:1587-1588.
37. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PLM, Mulligan LM, Zajak JD, Robinson BG, Eng C. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997;82:3902-3904.
38. Smith DP, Houghton C, Ponder BAJ. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 1997;15:1213-1217.
39. Hofstra RMW, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CHCM. A novel point mutation in the intracellular domain of the RET proto-oncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 1997;82:4176-4178.
40. Höppner W, Ritter MM. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 1997;6:587-590.
41. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, Höppner W. A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia. J Clin Endocrinol Metab 1998;83:770-774.
42. Dang GT, Cote GJ, Schultz PN, Khorana S, Decker RA, Gagel RF. A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes 1999;13:77-79.
43. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, Gagel RF, Takai S-I, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C. Genotype-phenotype correlation in MEN 2: Report of the International RET Mutation Consortium. J Intern Med 1995;238:343-346.
44. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN, Ponder BAJ. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet 1994;6:70-74.
45. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E, Rohmer V, Schlumberger M, Eng C, Guillausseau PJ, Lenoir GM. Risk and penetrance of primary hyperparathyroidism in MEN 2A families with codon 634 mutations of the RET proto-oncogene. J Clin Endocrinol Metab 1998;83:487-491.
46. Gimm O, Neuberg DS, Marsh DJ, Dahia PLM, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 1999;18:1369-1370.
47. Wells SA, Chi DD, Toshima D, Dehner LP, Coffin CM, Darton B, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF, Norton JA, Donis-Keller H. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;200:237-250.
48. Marsh DJ, Robinson BG, Andrew S, Richardson A-L, Pojer R, Schnitzler M, Mulligan LM, Hyland VJ. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 1994;23:477-479.
49. Lips CJM, Landsvater RM, Höppener JWM, Geerdink RA, Blijham G, Jansen-Schillhorn van Veen JM, van Gils APG, de Wit MJ, Zewald RA, Berends MJH, Beemer FA, Brouwers-Smalbraak J, Jansen RPM, Ploos van Amstel HK, J.M.V. vV, Vroom TM. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-835.
50. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1995;80:3088-3090.
51. Neumann HPH, Eng C, Mulligan LM, Glavac D, Zaüner I, Ponder BAJ, Crossey PA, Maher ER, Brauch H. Consequences of direct genetic testing for germ-line mutations in the clinical management of families with multiple endocrine neoplasia type 2. JAMA 1995;274:1149-1151.
52. McMahon R, Mulligan LM, Healey CS, Payne SJ, Ponder M, Ferguson-Smith MA, Barton DE, Ponder BAJ. Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families. Hum Mol Genet 1994;3:643-646.
53. Learoyd DL, Twigg SM, Marsh DJ, Robinson BG. The practical management of multiple endocrine neoplasia. Trend Endocrinol Metab 1995;6:273-278.
54. Decker RA, Peacock ML, Borst MJ, Sweet JD, Thompson NW Progress in genetic screening of multiple endocrine neoplasia type 2A: Is calcitonin testing obsolete?. Surgery 1995;118:257-264.
55. Offit K, Biesecker BB, Burt RW, Clayton EW, Garber JE, Kahn MJE. Statement of the American Society of Clinical Oncology -Genetic testing for cancer susceptibility. J Clin Oncol 1996; 14:1730-1736.
56. Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung disease. N Engl J Med 1996;335:943-951.
57. Carlomagno F, Salvatore G, Cirafici AM, Devita G, Melillo RM, Defranciscis V, Billaud M, Fusco A, Santoro M. The different RET activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 1997;57:391-395.
58. Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 1997;15:393-402.
59. Moers AMJ, Landsvater RM, Schaap C, Van Veen JMJS, DeValk IAJ, Blijham GH, Höppner JWM, Vroom TM, Van Amstel JKP, Lips CJM. Familial medullary thyroid carcinoma - not a distinct entity - genotype-phenotype correlation in a large family. Am J Med 1996;101:635-641.
60. Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirchsprung's disease phenotype. Cancer Res 1997;57:2870-2872.
61. Ponder BAJ, Finer N, Coffey R, Harmer CL, Maisey M, Ormerod MG, Pembrey ME, Ponder MA, Rosswick P, Shalet S, Group CMT. Family screening in medullary thyroid carcinoma presenting without a family history. Q J Med 1988;67:299-308.
62. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HPH, Ponder MA, Ponder BAJ. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 1995;43:123-127.
63. Wohlik N, Cote GJ, Bugalho MMJ, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:3740-3745.
64. Ponder BAJ. Multiple endocrine neoplasia type 2. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. New York: McGraw-Hill, 1998;475-487.